Biotechnology news
Biotechnology industry news covers news about business and scientific informationin of the biopharmaceutical market
Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI).
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results At CTOS Annual Meeting
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th.
DNA Molecules In Moss Open Door To New Biotechnology
Plasmids, which are DNA molecules capable of independent replication in cells, have played an important role in gene technology.
Novartis Receives Regulatory Approval In Germany For Celtura®, A Cell Culture-based Influenza A(H1N1) Pandemic Vaccine
Novartis announced that it received approval from the German regulatory authorities for its adjuvanted cell culture-based Influenza A(H1N1) 2009 monovalent vaccine, Celtura®. Novartis continues to pursue registration in other major countries, including Japan and Switzerland.
Lundbeck Starts Clinical Phase IIa With Lu AA24493 (cEPO) In Friedreich's Ataxia In A Study Also Assessing Efficacy Via Biomarkers
H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase IIa clinical studies with the innovative project Lu AA24493 in order to evaluate safety and tolerability and to explore theoretical efficacy parameters of the drug in humans. Lundbeck expects to enrol 35-40 people suffering from Friedreich's ataxia in this study.
Stimulus Grant To Help MSU Team Improve Drug Development From Plants
Scientists at Michigan State University are receiving nearly $3 million from the National Institutes of Health to uncover how several popular plants make medicinal compounds.
Ag Biotech Industry Stands Behind IRM Program
The agricultural biotechnology industry maintains that the Insect Resistance Management (IRM) Plan has been one of the most successful industry stewardship programs implemented since pest-tolerant biotech crops were introduced more than a decade ago.
DOJ Investigates Alleged Fraud By Drugmakers; Sanctions On WellCare Lifted
News outlets focus on alleged fraud in the drug and insurance industries. "A $112 million settlement involving alleged drug kickbacks that the Justice Dept. announced with the nation's largest nursing home pharmacy and a generic drug manufacturer on Nov. 3 is part of a wide-ranging investigation of suspected Medicaid fraud by the pharmaceutical industry,"
Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML).
Helix BioPharma Corp. Completes Enrollment In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts
Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) announced that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial. The double-blind and placebo-controlled Phase II trial is underway at multiple centers in Germany and Sweden.
